MedPlus Health Services Limited informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order from the Food and Drug Administration (FDA), Mumbai, for one of its stores in Vrindavan, Thane, Maharashtra.
The order, dated July 7, 2025, suspends the store’s drug license for a period of five days.
Reason for suspension
The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, for unspecified violations or contraventions of the applicable provisions.
Financial impact
MedPlus has estimated a potential revenue loss of approximately ₹2.25 lakh due to the suspension.
The company clarified that the impact is limited to the specific store in question and does not significantly affect its overall operations.
The disclosure was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer.
